The historical rank and industry rank for PureTech Health's OCF Margin % or its related term are showing as below:
PRTCY'
s OCF Margin % Range Over the Past 10 Years
Min: -14110.29 Med: -1706.75 Max: -444.67
Current: -1827.24
During the past 13 years, the highest OCF Margin % of PureTech Health was -444.67%. The lowest was -14110.29%. And the median was -1706.75%.
PRTCY's OCF Margin % is ranked worse than 84.36% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs PRTCY: -1827.24
PureTech Health OCF Margin % Related Terms
PureTech Health OCF Margin % Historical Data
* Premium members only.
The historical data trend for PureTech Health's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTCY vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, PureTech Health's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's OCF Margin % distribution charts can be found below:
* The bar in red indicates where PureTech Health's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a OCF Margin % of -1,395.62% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #809 out of 959 companies in the Biotechnology industry, placing it in the top 84.4%.
Is PureTech Health's OCF Margin % too high?
PureTech Health's current OCF Margin % is -1,395.62%. Based on the distribution chart, PureTech Health ranks #809 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #809 out of 959 companies for OCF Margin %. This places PureTech Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PureTech Health and its competitors. PureTech Health's current OCF Margin % is -1,395.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current OCF Margin % is -1,395.62%. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For PureTech Health (PRTCY), the current OCF Margin % is -1,395.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
OCF Margin %: -1,395.62%
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
